Endo International PLC (NASDAQ:ENDP) shares saw strong trading volume on Wednesday . 8,297,318 shares traded hands during mid-day trading, an increase of 21% from the previous session’s volume of 6,842,020 shares.The stock last traded at $22.50 and had previously closed at $22.16.

A number of research analysts have recently issued reports on the company. Vetr lowered Endo International PLC from a “hold” rating to a “strong sell” rating and set a $18.21 target price on the stock. in a report on Tuesday. JPMorgan Chase & Co. set a $40.00 target price on Endo International PLC and gave the company a “buy” rating in a report on Tuesday. Piper Jaffray Cos. set a $19.00 target price on Endo International PLC and gave the company a “hold” rating in a report on Tuesday. Leerink Swann reissued a “hold” rating and issued a $22.00 target price (down previously from $23.00) on shares of Endo International PLC in a report on Tuesday. Finally, BMO Capital Markets reissued a “hold” rating and issued a $22.00 target price on shares of Endo International PLC in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. Endo International PLC has a consensus rating of “Hold” and a consensus target price of $39.19.

The stock’s market cap is $4.96 billion. The company has a 50-day moving average price of $17.37 and a 200-day moving average price of $28.27.

Endo International PLC (NASDAQ:ENDP) last issued its earnings results on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.12. The company earned $921 million during the quarter, compared to analyst estimates of $873.50 million. The business’s revenue was up 25.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.08 earnings per share. Analysts anticipate that Endo International PLC will post $4.55 earnings per share for the current year.

Several hedge funds and institutional investors have modified their holdings of ENDP. RS Investment Management Co. LLC increased its position in shares of Endo International PLC by 29.5% in the fourth quarter. RS Investment Management Co. LLC now owns 543,593 shares of the company’s stock worth $33,279,000 after buying an additional 123,692 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock worth $16,737,000 after buying an additional 12,234 shares in the last quarter. American International Group Inc. increased its position in shares of Endo International PLC by 21.8% in the fourth quarter. American International Group Inc. now owns 99,335 shares of the company’s stock worth $6,081,000 after buying an additional 17,770 shares in the last quarter. Finally, Advantus Capital Management Inc increased its position in shares of Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock worth $1,223,000 after buying an additional 476 shares in the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.